Key facts
- This page summarizes Christopher Hite's Form 4 filing for Royalty Pharma plc (RPRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Feb 2025, 17:16.
Christopher Hite - 14 Feb 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)
- Reporting relationship
- EVP & Vice Chairman
- Issuer ticker
- RPRX
- Reported as of
- 14 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2025, 17:16:26 UTC
- Prior SEC filing
- 16 May 2024
- Next SEC filing
- 09 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Mehar, as Attorney-in-Fact for Christopher Hite
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Hite filed Form 4 for Royalty Pharma plc (RPRX) on 18 Feb 2025.
Change
- Previous filing in this sequence was filed on 16 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPRX
transaction
Class A Ordinary Shares
Conversion of derivative security
- Transaction value
- $0
- Shares
- +300,000
- Change %
- +100%
- Price
- $0.000000
- Shares after
- 600,000
- Date
- 14 Feb 2025
- Ownership
- By SCH Investment Partners LLC
- Footnotes
- F1
RPRX
holding
Class A Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 70,000
- Date
- 14 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RPRX
transaction
Derivative
LP interests in RPI US Partners 2019, LP
Conversion of derivative security
- Transaction value
- $0
- Shares
- -30,000
- Change %
- -26%
- Price
- $0.000000
- Shares after
- 86,641
- Date
- 14 Feb 2025
- Ownership
- By SCH Investment Partners LLC
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 300,000
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
Footnote F2
Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.